Crescent Biopharma, Inc. (CBIO)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1253689 · fiscal year ends in Dec
Closing price $14.09 on 29 Oct 2026; 52-week range $8.94 to $26.98.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $391.1M
- Cash
- $171.6M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 27.8M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $10.8M | -$152.6M | -$153.9M | – | -$72.5M | 10-K filed 26 Feb 2026 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $0 | -$24.8M | – |
| Q1 FY2026 | 31 Mar 2026 | $1.0M | -$23.3M | – |
| Q2 FY2025 | 30 Jun 2025 | $0 | -$21.8M | – |
| Q1 FY2025 | 31 Mar 2025 | $0 | -$15.1M | – |
| Q4 FY2024 | 31 Dec 2024 | $0 | -$17.9M | – |
Company events
The newest 8-K filings of 113 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 15 Oct 2026 | 8-K | Other events | 8.01 |
| 30 Jul 2026 | 8-K | Results | 2.02, 9.01 |
| 15 Jul 2026 | 8-K | Other events | 8.01, 9.01 |
| 14 Jul 2026 | 8-K | Results | 2.02 |
| 3 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 29 Apr 2026 | 8-K | Results | 2.02, 9.01 |
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Dec 2025 | 8-K | Material agreement, Share sale, Investor update, Other events | 1.01, 3.02, 7.01, 8.01, 9.01 |
| 6 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 31 Jul 2025 | 8-K | Results, Leadership change | 2.02, 5.02, 9.01 |
| 18 Jun 2025 | 8-K | Change in control, Results, Deal completed, Leadership change, Material agreement, Auditor change, Shareholder rights change, Bylaws or fiscal year change, Code of ethics change, Shell company status, Investor update | 1.01, 2.01, 2.02, 3.03, 4.01, 5.01, 5.02, 5.03, 5.05, 5.06, 7.01, 9.01 |
| 6 Jun 2025 | 8-K | Shareholder vote, Investor update, Other events | 5.07, 7.01, 8.01, 9.01 |
Every filing
The newest filings with the SEC of 274 held.
| Filed | Form | Period |
|---|---|---|
| 15 Oct 2026 | 8-K | 15 Oct 2026 |
| 18 Sep 2026 | S-8 | – |
| 31 Jul 2026 | EFFECT | – |
| 30 Jul 2026 | POS AM | – |
| 30 Jul 2026 | 10-Q | 30 Jun 2026 |
| 30 Jul 2026 | 8-K | 30 Jul 2026 |
| 15 Jul 2026 | 8-K | 14 Jul 2026 |
| 14 Jul 2026 | 8-K | 14 Jul 2026 |
| 10 Jul 2026 | EFFECT | – |
| 1 Jul 2026 | S-3 | – |
| 22 Jun 2026 | 10-Q/A | 31 Mar 2026 |
| 3 Jun 2026 | 8-K | 2 Jun 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 18 Sep 2026 | Brumm Joshua T, Chief Executive Officer | Sale under a trading plan | 7,837 | $16.71 | $131.0K | 271,765 | 18 Sep 2026 |
| 18 Sep 2026 | Mcneill Jonathan, President and COO | Sale under a trading plan | 3,839 | $16.71 | $64.2K | 134,588 | 18 Sep 2026 |
| 16 Sep 2026 | Lynch Ryan, See Remarks | Sale under a trading plan | 240 | $17.90 | $4.3K | 13,631 | 18 Sep 2026 |
| 16 Sep 2026 | Pinkas Jan, Chief Scientific Officer | Sale under a trading plan | 658 | $17.90 | $11.8K | 21,581 | 18 Sep 2026 |
| 16 Sep 2026 | Im Ellie Eunkyung, Chief Medical Officer | Sale under a trading plan | 623 | $17.90 | $11.2K | 21,446 | 18 Sep 2026 |
| 16 Sep 2026 | Scalzo Richard William, Chief Financial Officer | Sale under a trading plan | 568 | $17.90 | $10.2K | 19,730 | 18 Sep 2026 |
| 16 Sep 2026 | Bispham Barbara Harlin, See Remarks | Sale under a trading plan | 620 | $17.90 | $11.1K | 18,710 | 18 Sep 2026 |
| 16 Sep 2026 | Brumm Joshua T, Chief Executive Officer | Sale under a trading plan | 1,610 | $17.90 | $28.8K | 279,602 | 18 Sep 2026 |
| 16 Sep 2026 | Mcneill Jonathan, President and COO | Sale under a trading plan | 731 | $17.90 | $13.1K | 138,427 | 18 Sep 2026 |
| 16 Jul 2026 | Fairmount Funds Management Llc, Director | Purchase | 853,450 | $14.50 | $12.4M | 3,601,316 | 20 Jul 2026 |
| 22 Jun 2026 | Lynch Ryan, See Remarks | Sale under a trading plan | 465 | $17.99 | $8.4K | 13,871 | 23 Jun 2026 |
| 22 Jun 2026 | Pinkas Jan, Chief Scientific Officer | Sale under a trading plan | 1,288 | $17.99 | $23.2K | 22,239 | 23 Jun 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 17 Sep 2026 | Jonathan McNeill, Officer | 4,415 | $75.8K | 18 Sep 2026 |
| 17 Sep 2026 | Joshua T Brumm, Officer, Director | 9,013 | $154.8K | 18 Sep 2026 |
| 16 Sep 2026 | Jonathan McNeill, Officer | 804 | $15.1K | 16 Sep 2026 |
| 16 Sep 2026 | Joshua T Brumm, Officer, Director | 1,771 | $33.3K | 16 Sep 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Oct 2026 | BlackRock, Inc. | 13G | 5.6% | 2.1M |
| 14 Aug 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G amended | 6.03% | 1.7M |
| 20 Jul 2026 | Fairmount Funds Management LLC | 13D amended | 16.52% | 6.6M |
| 15 May 2026 | TANG CAPITAL MANAGEMENT, LLC | 13G amended | 4.21% | 1.2M |
| 15 May 2026 | Balyasny Asset Management L.P. | 13G | 5.48% | 1.5M |
| 17 Feb 2026 | Venrock Healthcare Capital Partners III, L.P. | 13G amended | 9.5% | 2.7M |
| 17 Feb 2026 | Vestal Point Capital, LP | 13G | 5.4% | 1.5M |
| 5 Feb 2026 | FMR LLC | 13G amended | 15% | 4.1M |
| 11 Dec 2025 | ForGrowth III PA B.V. | 13G | 6.1% | 1.7M |
| 8 Dec 2025 | Fairmount Funds Management LLC | 13D amended | 18.53% | 5.6M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 4.4M | -7.49% | 12.66 |
| 30 Sep 2026 | 4.8M | +40.21% | 6.85 |
| 15 Sep 2026 | 3.4M | +7.4% | 8.51 |
| 31 Aug 2026 | 3.2M | -1.38% | 19.91 |
| 14 Aug 2026 | 3.2M | -7.17% | 17.13 |
| 31 Jul 2026 | 3.5M | -7.43% | 8.92 |
| 15 Jul 2026 | 3.7M | +1.9% | 9.73 |
| 30 Jun 2026 | 3.7M | +9.77% | 7.03 |
Funds that hold it
From each fund's latest Form 13F.
92 funds held it at 30 Jun 2026: 48 added and 14 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| FMR LLC | 4,133,514 | $74.4M | 0 |
| BVF Inc. | 2,748,763 | $49.5M | 0 |
| Fairmount Funds Management LLC | 2,747,866 | $49.5M | 0 |
| Venrock Adviser, LLC | 2,133,576 | $38.4M | 0 |
| Logos Global Management LP | 1,900,000 | $34.2M | +1,417,500 |
| Fcpm III Services B.V. | 1,677,852 | $30.2M | 0 |
| Balyasny Asset Management L.P. | 1,662,917 | $29.9M | +152,884 |
| Vestal Point Capital, LP | 1,630,000 | $29.3M | +130,000 |
| Opaleye Management Inc. | 1,319,351 | $23.7M | +6,736 |
| BlackRock, Inc. | 1,271,762 | $22.9M | +1,156,037 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B